Delcath Systems Inc expected to post a loss of 9 cents a share - Earnings Preview
Delcath Systems Inc expected to post a loss of 9 cents a share - Earnings Preview
Delcath Systems Inc DCTH.OQ DCTH.O is expected to show a rise in quarterly revenue when it reports results on August 6 for the period ending June 30 2026
The Queensbury New York-based company is expected to report a 8.7% increase in revenue to $26.259 million from $24.16 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Delcath Systems Inc is for a loss of 9 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Delcath Systems Inc is $21.50, about 64.9% above its last closing price of $13.04
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.08 | -0.09 | -0.03 | Beat | 65.4 |
Dec. 31 2026 | -0.05 | -0.06 | -0.05 | Beat | 18.9 |
Sep. 30 2025 | 0.02 | 0.02 | 0.02 | Met | 0 |
Jun. 30 2025 | 0.02 | 0.03 | 0.07 | Beat | 180 |
Mar. 31 2025 | 0.03 | 0.02 | 0.03 | Beat | 100 |
Dec. 31 2024 | 0.02 | -0.02 | -0.11 | Missed | -500.1 |
Sep. 30 2024 | -0.10 | -0.20 | 0.06 | Beat | 130 |
Jun. 30 2024 | -0.37 | -0.36 | -0.48 | Missed | -32.7 |
This summary was machine generated August 4 at 13:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Delcath Systems
See all newsBrief: Delcath Systems Highlights Clinical Program Presentations At Esmo Congress 2026 And Independent Data On Percutaneous Hepatic Perfusion In Liver-Dominant Metastatic Uveal Melanoma
Brief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule
Delcath Systems Inc reports results for the quarter ended June 30 - Earnings Summary
Delcath Systems Q2 revenue rises, beats estimates
Delcath Systems Inc expected to post a loss of 9 cents a share - Earnings Preview